Daewoong Pharmaceutical announced on March 14 that its product Fexuclue (ingredient name: fexuprazan HCl), a treatment for gastroesophageal reflux disease, obtained a drug license from the Agencia Nacional de Medicamentos, or ANAMED, under the Chilean Public Health Institute on Feb. 20. This marked the second consecutive month that Daewoong Pharmaceutical has obtained approval for the medicine in Latin America, following Ecuador in January.
http://www.businesskorea.co.kr/news/articleView.html?idxno=110950
No comments:
Post a Comment